|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquired
|
Global Health Corp
|
|
gptkbp:awards
|
Best Pharma Company 2022
|
|
gptkbp:benefits
|
gptkb:healthcare_organization
|
|
gptkbp:ceo
|
gptkb:John_Burns
|
|
gptkbp:clinical_trial
|
Cardiovascular Studies
Phase 1, Phase 2, Phase 3
2000 patients
Phase 3 Trials for Heart Med
|
|
gptkbp:collaborations
|
University of Medicine
|
|
gptkbp:community_involvement
|
Free Health Camps
|
|
gptkbp:conference
|
Burns Pharma Summit
|
|
gptkbp:distribution
|
Pharmacies and Hospitals
|
|
gptkbp:employees
|
gptkb:500
|
|
gptkbp:established
|
Dr. Emily Burns
|
|
gptkbp:financial_performance
|
Annual Report 2022
|
|
gptkbp:founded
|
gptkb:1990
|
|
gptkbp:global_presence
|
10 countries
|
|
gptkbp:grants
|
$5 million from NIH
|
|
gptkbp:headquarters
|
gptkb:New_York,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Burns Pharmaceuticals
|
|
gptkbp:invention
|
10 active patents
|
|
gptkbp:investment
|
AI in Drug Discovery
Investor Day 2023
$50 million in R& D
|
|
gptkbp:market
|
gptkb:North_America
15% in cardiovascular sector
Cardiovascular Market Trends
Heart Med 2023
|
|
gptkbp:partnership
|
Cardio Health Foundation
|
|
gptkbp:partnerships
|
Health Innovations Inc.
|
|
gptkbp:philanthropy
|
$1 million to Health NG Os
|
|
gptkbp:products
|
Blood Pressure Plus
Cholesterol Care
Heart Med
|
|
gptkbp:regulatory_compliance
|
FDA Approved
|
|
gptkbp:research
|
Dr. Sarah Lee
|
|
gptkbp:research_focus
|
Chronic Diseases
|
|
gptkbp:revenue
|
$200 million
|
|
gptkbp:social_responsibility
|
Community Health Initiatives
|
|
gptkbp:specializes_in
|
Cardiovascular Drugs
|
|
gptkbp:student_enrollment
|
85%
|
|
gptkbp:subsidiary
|
Burns Biotech
|
|
gptkbp:supply_chain
|
Global Suppliers
|
|
gptkbp:sustainability
|
Eco-friendly Packaging
|
|
gptkbp:training
|
Leadership Development
|
|
gptkbp:website
|
www.burnspharma.com
|
|
gptkbp:bfsParent
|
gptkb:Chief_Burns
|
|
gptkbp:bfsLayer
|
5
|